A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration


Trial ID: NCT02247531


This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Official Title

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Stanford Investigator(s)

Theodore Leng, MD, FACS
Theodore Leng, MD, FACS

Associate Professor of Ophthalmology and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine (Adult MSD)


Inclusion Criteria:

   - Participants aged greater than or equal to (>/=) 50 years

   - Well demarcated area(s) of Geographic Atrophy (GA) secondary to Age-Related Macular
   Degeneration (AMD) with no evidence of prior or active choroidal neovascularization
   (CNV) in both eyes

Exclusion Criteria:

Ocular Exclusion Criteria (Study Eye):

   - History of vitrectomy surgery, submacular surgery, or other surgical intervention for

   - Previous laser photocoagulation for CNV, diabetic macular edema, retinal vein
   occlusion, and proliferative diabetic retinopathy

   - Previous intravitreal drug delivery (e.g., intravitreal corticosteroid injection,
   anti-angiogenic drugs, anti-complement agents, or device implantation)

Ocular Exclusion Criteria (Both Eyes):

   - GA in either eye due to causes other than AMD

   - Previous treatment with eculizumab, lampalizumab, and/or fenretinide


drug: Lampalizumab

other: Sham Comparator


Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305